Journal of Reproductive Immunology
Volume 86, Issue 2 , Pages 133-140 , November 2010

Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies

  • M. Angeles Martínez-Zamora

      Affiliations

    • Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    • ,
  • Dolors Tassies

      Affiliations

    • Department of Hemotherapy and Hemostasis, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    • ,
  • Francisco Carmona

      Affiliations

    • Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    • ,
  • Gerard Espinosa

      Affiliations

    • Deparment of Autoimmune Diseases, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    • ,
  • Ricard Cervera

      Affiliations

    • Deparment of Autoimmune Diseases, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    • ,
  • Juan Carlos Reverter

      Affiliations

    • Department of Hemotherapy and Hemostasis, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    • ,
  • Juan Balasch

      Affiliations

    • Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    • Corresponding Author InformationCorresponding author at: Institut Clínic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel, 170, 08036 Barcelona, Spain. Tel.: +34 932275436; fax: +34 932279325.

Received 14 February 2010 ,Revised 18 May 2010 ,Accepted 18 May 2010.

References 

  1. Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, et al. Effects of aspirin on clot lysis structure and fibrinolysis using a novel in vitro cellular system. Arterioscler. Thromb. Vasc. Biol. 2009;29:712–717
  2. Akatsu H, Yamagata H, Chen Y, Miki T, Kamino K, Takeda M. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction. Br. J. Haematol. 2004;127:440–447
  3. Alacacioglu I, Ozcan MA, Alacacioglu A, Polat M, Yuksel F, Demirkan F, et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb. Res. 2004;114:155–159
  4. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002;101:6–14
  5. American College of Obstetrics and Gynecology . ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. No. 33, January 2002. Obstet. Gynecol. Obstet. 2002;99:159–167
  6. American College of Obstetrics and Gynecology . ACOG practice bulletin. Perinatal care at the threshold of viability. No. 38, September 2002. Int. J. Gynaecol. Obstet. 2002;79:181–188
  7. Antovic JP, Rafik Hamad R, Antovic A, Blomback M, Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb. Haemost. 2002;88:644–647
  8. Balasch J, Carmona F, Creus M, Font J, Cervera R. Management of reproductive failure in the antiphospholipid syndrome. In:  Asherson RA,  Cervera R,  Piette R-C,  Schoenfeld Y editor. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Amsterdam: Elsevier Science B.V.; 2002;p. 375–394
  9. Bjornsson TD, Schneider DE, Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J. Pharmacol. Exp. Ther. 1989;250:154–161
  10. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypectidase U). J. Thromb. Haemost. 2003;1:1566–1574
  11. Branch DW, Silver R, Blackwell J, Reading J, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet. Gynecol. 1992;80:614–620
  12. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria the diagnosis of lupus anticoagulant: an update. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost. 1995;74:1185–1190
  13. Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneide RM, Boffa M. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood. 2001;98:1193–1992
  14. Carmona F, Font J, Azulay M, Creus M, Fabregues F, Cervera R, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am. J. Reprod. Immunol. 2001;46:274–279
  15. Carmona F, Lazaro I, Reverter JC, Taséis D, Font J, Cervera R, et al. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. Am. J. Obstet. Gynecol. 2006;194:457–465
  16. Cellai AP, Antonucci E, Liotta AA, Fedi S, Marcucci R, Falciani M. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb. Res. 2006;118:494–500
  17. Chabloz P, Reber G, Boehlen F, Hohlfeld P, De Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br. J. Haematol. 2001;115:150–152
  18. Chetaille P, Alessi MC, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb. Haemost. 2000;83:902–905
  19. Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb. Haemost. 2002;88:282–287
  20. Curnow JL, Morel-Kopp M-C, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J. Thromb. Haemost. 2006;5:528–534
  21. De Maat MPM, Jansen MWJC, Hille ETM, Vos HL, Bloemerkamp KWM, Buitendkijk S, et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J. Thromb. Haemost. 2004;2:1588–1593
  22. Eichinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004;103:3773–3776
  23. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun. Rev. 2003;2:86–93
  24. Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus. 2008;17:872–877
  25. Franco RF, Fagundes MG, Meijers JC, Meijers JC, Reitsma PH, Lourenço D, et al. Identification of polymorphisms in the 5′-untranslated region of the tafi gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica. 2001;86:510–517
  26. Gils A, Alessi MC, Browers E, Peeters M, Marx P, Leurs J, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler. Thromb. Vasc. Biol. 2003;23:1122–1127
  27. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb. Res. 2005;116:345–356
  28. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001;97:2053–2058
  29. Lisman T, Leebek FWG, Meijer K, Van Der Meer J, Nieuwenhuis K, De Groot P. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology. 2002;35:616–621
  30. Lisman T, deGroot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk for venous thrombosis. Blood. 2005;105:1102–1105
  31. Martínez-Zamora MA, Tassies D, Carmona F, Espinosa G, Cervera R, Reverter JC, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (clot lysis time) in pregnant patients with antiphospholipid syndrome (APS): relationship with pregnancy outcome and thrombosis. Am. J. Reprod. Immunol. 2009;62:381–389
  32. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006;4:295–306
  33. Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiller D. Association between TAFI antigen and Ala 147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb. Haemost. 2003;89:554–560
  34. Mousa HA, Downey C, Alfirevic Z, Toh C. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb. Haemost. 2004;92:1025–1031
  35. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001;357:53–56
  36. Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke. 2003;34:2387–2391
  37. Sartori MT, Serena A, Saggiorato G, Campei S, Faggian D, Pagnan A. Variations in fibrinolytic parameters and inhibin-A in pregnancy: related hypertensive disorders. J. Thromb. Haemost. 2007;6:352–358
  38. Schatteman KA, Goosens FJ, Scharpe SS, Hendriks DF. Proteolytic activation of purified human procarboxypeptidase U. Clin. Chim. Acta. 2000;292:25–40
  39. Schroeder V, Kucher N, Kohler HP. Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism. J. Thromb. Haemost. 2003;1:492–493
  40. Sucak GT, Acar K, Sucak A, Kirazli S, Haznedar R. Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia. Blood Coagul. Fibrinolysis. 2006;17:347–352
  41. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855–2859
  42. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 1998;273:27176–27181
  43. Watanabe T, Minakami H, Sakata Y, Matsubara S, Sato I, Suzuki M. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy. Gynecol. Obstet. Invest. 2004;58:19–21
  44. Wiwanitkit V. Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal. Arch. Gynecol. Obstet. 2006;273:322–324

PII: S0165-0378(10)00095-1

doi: 10.1016/j.jri.2010.05.002

Journal of Reproductive Immunology
Volume 86, Issue 2 , Pages 133-140 , November 2010

Article Tools

* Image Usage & Resolution